Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has awarded stock options to two new employees as employment inducement grants.

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has awarded stock options to two new employees as employment inducement grants. The options total 95,100 shares of common stock with an exercise price of $3.14 per share, matching the closing price on August 29, 2025.

The options feature a four-year vesting schedule, with 25% vesting after one year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The options have a 10-year term and are governed by Akebia's inducement award program and stock option agreements.

Argus Sep 3 session

+0.32% close to close Open Argus

Details

News Market Reaction – AKBA

On Sep 3, the first trading day after this news, AKBA closed 0.32% above the previous close.

Data tracked by StockTitan Argus for the Sep 3 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 95,100 shares of Akebia’s common stock on August 29, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $3.14 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What type of stock options did Akebia Therapeutics (AKBA) grant to new employees in August 2025?

Akebia granted options to purchase 95,100 shares of common stock at $3.14 per share, with a four-year vesting schedule and 10-year term.

What is the vesting schedule for Akebia Therapeutics' (AKBA) August 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, subject to continued employment.

Why did Akebia Therapeutics (AKBA) issue these stock options in August 2025?

The options were granted as inducement material for two newly-hired employees entering into employment with Akebia, in accordance with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of Akebia Therapeutics' (AKBA) August 2025 inducement grants?

The exercise price is $3.14 per share, which equals the closing price of Akebia's common stock on the grant date of August 29, 2025.